|
|
|
|
| LEADER |
01367nam a2200241Ia 4500 |
| 001 |
10.4103-aca.aca_98_21 |
| 008 |
220718s2022 CNT 000 0 und d |
| 020 |
|
|
|a 09745181 (ISSN)
|
| 245 |
1 |
0 |
|a Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: A case series
|
| 260 |
|
0 |
|b NLM (Medline)
|c 2022
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.4103/aca.aca_98_21
|
| 520 |
3 |
|
|a Catecholamine-resistant postoperative vasoplegic syndrome (PVS) lacks effective treatment modalities. Synthetic angiotensin II was recently approved for the treatment of vasodilatory shock; however, its use in PVS is not well described. We report outcomes in six patients receiving angiotensin II for the treatment of isolated PVS. All patients achieved their MAP goal and the majority showed improvement in lactate and background catecholamine dose; however, variables of perfusion changed discordantly. Three of six patients survived to hospital discharge.
|
| 650 |
0 |
4 |
|a Angiotensin II
|
| 650 |
0 |
4 |
|a cardiac vasoplegia
|
| 650 |
0 |
4 |
|a case report
|
| 650 |
0 |
4 |
|a postoperative vasoplegic syndrome
|
| 650 |
0 |
4 |
|a shock
|
| 700 |
1 |
|
|a Enfield, K.B.
|e author
|
| 700 |
1 |
|
|a Hulse, M.C.
|e author
|
| 700 |
1 |
|
|a Konkol, S.B.
|e author
|
| 700 |
1 |
|
|a Mihalek, A.D.
|e author
|
| 700 |
1 |
|
|a Morrisette, M.J.
|e author
|
| 773 |
|
|
|t Annals of cardiac anaesthesia
|
